Sanofi's quiet Sarclisa chalks up a first-in-class win with eyes on a first-line multiple myeloma nod
Fierce Pharma
DECEMBER 7, 2023
In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. |
Let's personalize your content